Teduglutide is a glucagon-like peptide-2 (GLP- 2) receptor agonist used for the treatment of short-bowel syndrome. Teduglutide has similar binding affinity, agonist potency, and agonist efficacy as GLP-2 in assays with the rat GLP-2 receptor. Administration of teduglutide to rats gave a significant increase in small intestine weight and an increase in the height of intestinal villi.
|Body Surface Area (m2)||0.007||0.025||0.15||0.05||0.02||0.5|
|Animal A (mg/kg) = Animal B (mg/kg) multiplied by||Animal B Km|
|Animal A Km|
For example, to modify the dose of Compound A used for a mouse (20 mg/kg) to a dose based on the BSA for a rat, multiply 20 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for Compound A of 10 mg/kg.
|Related Glucagon Receptor Products|
LSN3318839 is an orally active allosteric modulator of glucagon-like peptide-1 receptor (GLP-1R).
|GLP-1(7-36), amide TFA
TFA is a major intestinal hormone that stimulates insulin secretion by pancreatic beta cells in response to glucose.
Glp-1 (7-37) is an intestinal insulin hormone that enhances glucose-induced insulin secretion.
PF-06882961 is a potent, orally bioavailable agonist of the glucagon-like peptide-1 receptor (GLP-1R) agonist.
NNC0640 is a potent, negative allosteric modulator (NAM) of human G-protein-coupled glucagon receptor (GCGR) with IC50 of 69.2 nM.
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2020 AbMole BioScience. All Rights Reserved.